Atopic dermatitis: improved itch symptoms with dupilumab in multitrial analysis

  • Silverberg JI & al.
  • J Am Acad Dermatol
  • 2 Mar 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Dupilumab is associated with improvements in pruritus symptoms in adults and adolescents with atopic dermatitis, according to results from 4 phase 3 clinical trials.

Why this matters

  • Pruritus is a major symptom of atopic dermatitis, and these results further support a beneficial role for dupilumab.

Key results

  • Dupilumab was associated with a greater improvement (least-squares mean percentage change) in daily Peak Pruritus Numerical Rating Scale score compared with placebo (P<.0001 for all style="list-style-type:circle;">
  • −47.4% vs −20.5% at 16 weeks in the SOLO 1/2 trials (adult patients, dupilumab 300 mg every 2 weeks or placebo monotherapy).
  • −47.9% vs −19.0% at 16 weeks in the AD-ADOL trial (adolescent patients, dupilumab 200 mg baseline weight
  • −57.3% vs −30.9% at 52 weeks in the CHRONOS trial (adult patients, dupilumab 300 mg every 2 weeks or placebo with concomitant topical corticosteroids).

Study design

  • 1505 patients with moderate to severe atopic dermatitis from 4 randomized controlled studies were included.
  • Funding: Sanofi; Regeneron Pharmaceuticals, Inc.

Limitations

  • Short duration (16 weeks) of monotherapy trials.